PMC:7253235 / 42506-43184 JSONTXT

Annnotations TAB JSON ListView MergeView

    LitCovid-PubTator

    {"project":"LitCovid-PubTator","denotations":[{"id":"1381","span":{"begin":30,"end":38},"obj":"Species"},{"id":"1382","span":{"begin":392,"end":399},"obj":"Species"},{"id":"1383","span":{"begin":426,"end":434},"obj":"Species"},{"id":"1412","span":{"begin":147,"end":161},"obj":"Disease"},{"id":"1413","span":{"begin":340,"end":352},"obj":"Disease"},{"id":"1414","span":{"begin":543,"end":546},"obj":"Disease"},{"id":"1415","span":{"begin":579,"end":585},"obj":"Disease"}],"attributes":[{"id":"A1381","pred":"tao:has_database_id","subj":"1381","obj":"Tax:9606"},{"id":"A1382","pred":"tao:has_database_id","subj":"1382","obj":"Tax:9606"},{"id":"A1383","pred":"tao:has_database_id","subj":"1383","obj":"Tax:9606"},{"id":"A1412","pred":"tao:has_database_id","subj":"1412","obj":"MESH:D066126"},{"id":"A1413","pred":"tao:has_database_id","subj":"1413","obj":"MESH:D050171"},{"id":"A1415","pred":"tao:has_database_id","subj":"1415","obj":"MESH:D009369"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"• Minimize cardiac imaging to patients who are symptomatic\n• Multidisciplinary discussion with hematologist/oncologist about reducing frequency of cardiotoxicity screening, especially if prior serial testing unremarkable\n• Limited imaging protocols to evaluate LVEF to minimize acquisition time\n• Defer primary prevention assessment (i.e., dyslipidemia management) unless critical to care of patient\n• Telemedicine visits for patients who do not require face-to-face assessment for medical issues (i.e., blood pressure/lipid management/stable CHF)\n• Defer asymptomatic long-term cancer survivor surveillance (i.e., assessment of ventricular and valvular function) if no symptoms"}

    LitCovid-PD-FMA-UBERON

    {"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T118","span":{"begin":454,"end":458},"obj":"Body_part"},{"id":"T119","span":{"begin":462,"end":466},"obj":"Body_part"},{"id":"T120","span":{"begin":504,"end":509},"obj":"Body_part"},{"id":"T121","span":{"begin":519,"end":524},"obj":"Body_part"}],"attributes":[{"id":"A118","pred":"fma_id","subj":"T118","obj":"http://purl.org/sig/ont/fma/fma24728"},{"id":"A119","pred":"fma_id","subj":"T119","obj":"http://purl.org/sig/ont/fma/fma24728"},{"id":"A120","pred":"fma_id","subj":"T120","obj":"http://purl.org/sig/ont/fma/fma9670"},{"id":"A121","pred":"fma_id","subj":"T121","obj":"http://purl.org/sig/ont/fma/fma67264"}],"text":"• Minimize cardiac imaging to patients who are symptomatic\n• Multidisciplinary discussion with hematologist/oncologist about reducing frequency of cardiotoxicity screening, especially if prior serial testing unremarkable\n• Limited imaging protocols to evaluate LVEF to minimize acquisition time\n• Defer primary prevention assessment (i.e., dyslipidemia management) unless critical to care of patient\n• Telemedicine visits for patients who do not require face-to-face assessment for medical issues (i.e., blood pressure/lipid management/stable CHF)\n• Defer asymptomatic long-term cancer survivor surveillance (i.e., assessment of ventricular and valvular function) if no symptoms"}

    LitCovid-PD-UBERON

    {"project":"LitCovid-PD-UBERON","denotations":[{"id":"T55","span":{"begin":454,"end":458},"obj":"Body_part"},{"id":"T56","span":{"begin":462,"end":466},"obj":"Body_part"},{"id":"T57","span":{"begin":504,"end":509},"obj":"Body_part"}],"attributes":[{"id":"A55","pred":"uberon_id","subj":"T55","obj":"http://purl.obolibrary.org/obo/UBERON_0001456"},{"id":"A56","pred":"uberon_id","subj":"T56","obj":"http://purl.obolibrary.org/obo/UBERON_0001456"},{"id":"A57","pred":"uberon_id","subj":"T57","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"}],"text":"• Minimize cardiac imaging to patients who are symptomatic\n• Multidisciplinary discussion with hematologist/oncologist about reducing frequency of cardiotoxicity screening, especially if prior serial testing unremarkable\n• Limited imaging protocols to evaluate LVEF to minimize acquisition time\n• Defer primary prevention assessment (i.e., dyslipidemia management) unless critical to care of patient\n• Telemedicine visits for patients who do not require face-to-face assessment for medical issues (i.e., blood pressure/lipid management/stable CHF)\n• Defer asymptomatic long-term cancer survivor surveillance (i.e., assessment of ventricular and valvular function) if no symptoms"}

    LitCovid-PD-MONDO

    {"project":"LitCovid-PD-MONDO","denotations":[{"id":"T424","span":{"begin":340,"end":352},"obj":"Disease"},{"id":"T425","span":{"begin":543,"end":546},"obj":"Disease"},{"id":"T426","span":{"begin":579,"end":585},"obj":"Disease"}],"attributes":[{"id":"A424","pred":"mondo_id","subj":"T424","obj":"http://purl.obolibrary.org/obo/MONDO_0002525"},{"id":"A425","pred":"mondo_id","subj":"T425","obj":"http://purl.obolibrary.org/obo/MONDO_0005009"},{"id":"A426","pred":"mondo_id","subj":"T426","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"}],"text":"• Minimize cardiac imaging to patients who are symptomatic\n• Multidisciplinary discussion with hematologist/oncologist about reducing frequency of cardiotoxicity screening, especially if prior serial testing unremarkable\n• Limited imaging protocols to evaluate LVEF to minimize acquisition time\n• Defer primary prevention assessment (i.e., dyslipidemia management) unless critical to care of patient\n• Telemedicine visits for patients who do not require face-to-face assessment for medical issues (i.e., blood pressure/lipid management/stable CHF)\n• Defer asymptomatic long-term cancer survivor surveillance (i.e., assessment of ventricular and valvular function) if no symptoms"}

    LitCovid-PD-CLO

    {"project":"LitCovid-PD-CLO","denotations":[{"id":"T310","span":{"begin":200,"end":207},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T311","span":{"begin":454,"end":458},"obj":"http://purl.obolibrary.org/obo/UBERON_0001456"},{"id":"T312","span":{"begin":462,"end":466},"obj":"http://purl.obolibrary.org/obo/UBERON_0001456"},{"id":"T313","span":{"begin":504,"end":509},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"T314","span":{"begin":504,"end":509},"obj":"http://www.ebi.ac.uk/efo/EFO_0000296"}],"text":"• Minimize cardiac imaging to patients who are symptomatic\n• Multidisciplinary discussion with hematologist/oncologist about reducing frequency of cardiotoxicity screening, especially if prior serial testing unremarkable\n• Limited imaging protocols to evaluate LVEF to minimize acquisition time\n• Defer primary prevention assessment (i.e., dyslipidemia management) unless critical to care of patient\n• Telemedicine visits for patients who do not require face-to-face assessment for medical issues (i.e., blood pressure/lipid management/stable CHF)\n• Defer asymptomatic long-term cancer survivor surveillance (i.e., assessment of ventricular and valvular function) if no symptoms"}

    LitCovid-PD-CHEBI

    {"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T120","span":{"begin":519,"end":524},"obj":"Chemical"}],"attributes":[{"id":"A120","pred":"chebi_id","subj":"T120","obj":"http://purl.obolibrary.org/obo/CHEBI_18059"}],"text":"• Minimize cardiac imaging to patients who are symptomatic\n• Multidisciplinary discussion with hematologist/oncologist about reducing frequency of cardiotoxicity screening, especially if prior serial testing unremarkable\n• Limited imaging protocols to evaluate LVEF to minimize acquisition time\n• Defer primary prevention assessment (i.e., dyslipidemia management) unless critical to care of patient\n• Telemedicine visits for patients who do not require face-to-face assessment for medical issues (i.e., blood pressure/lipid management/stable CHF)\n• Defer asymptomatic long-term cancer survivor surveillance (i.e., assessment of ventricular and valvular function) if no symptoms"}

    LitCovid-PD-HP

    {"project":"LitCovid-PD-HP","denotations":[{"id":"T237","span":{"begin":340,"end":352},"obj":"Phenotype"},{"id":"T238","span":{"begin":543,"end":546},"obj":"Phenotype"},{"id":"T239","span":{"begin":579,"end":585},"obj":"Phenotype"}],"attributes":[{"id":"A237","pred":"hp_id","subj":"T237","obj":"http://purl.obolibrary.org/obo/HP_0003119"},{"id":"A238","pred":"hp_id","subj":"T238","obj":"http://purl.obolibrary.org/obo/HP_0001635"},{"id":"A239","pred":"hp_id","subj":"T239","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"• Minimize cardiac imaging to patients who are symptomatic\n• Multidisciplinary discussion with hematologist/oncologist about reducing frequency of cardiotoxicity screening, especially if prior serial testing unremarkable\n• Limited imaging protocols to evaluate LVEF to minimize acquisition time\n• Defer primary prevention assessment (i.e., dyslipidemia management) unless critical to care of patient\n• Telemedicine visits for patients who do not require face-to-face assessment for medical issues (i.e., blood pressure/lipid management/stable CHF)\n• Defer asymptomatic long-term cancer survivor surveillance (i.e., assessment of ventricular and valvular function) if no symptoms"}

    LitCovid-sentences

    {"project":"LitCovid-sentences","denotations":[{"id":"T269","span":{"begin":59,"end":220},"obj":"Sentence"},{"id":"T270","span":{"begin":221,"end":294},"obj":"Sentence"},{"id":"T271","span":{"begin":295,"end":399},"obj":"Sentence"},{"id":"T272","span":{"begin":400,"end":547},"obj":"Sentence"},{"id":"T273","span":{"begin":548,"end":678},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"• Minimize cardiac imaging to patients who are symptomatic\n• Multidisciplinary discussion with hematologist/oncologist about reducing frequency of cardiotoxicity screening, especially if prior serial testing unremarkable\n• Limited imaging protocols to evaluate LVEF to minimize acquisition time\n• Defer primary prevention assessment (i.e., dyslipidemia management) unless critical to care of patient\n• Telemedicine visits for patients who do not require face-to-face assessment for medical issues (i.e., blood pressure/lipid management/stable CHF)\n• Defer asymptomatic long-term cancer survivor surveillance (i.e., assessment of ventricular and valvular function) if no symptoms"}